Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

475
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
475
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

561
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
561
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

816
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
816
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

97
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
97
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

124
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
124

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Better care and improved outcomes if your patients are enrolled in a research programme.

European heart journal. Quality of care & clinical outcomes·2026
Same author

Artificial Intelligence in Biomedical Scientific Publishing.

European heart journal·2026
Same author

Environmental risk factors and cardiovascular health.

European heart journal·2026
Same author

Implementation of quality of care in heart failure and in predisposing conditions.

European heart journal. Quality of care & clinical outcomes·2026
Same author

Climate Change and Cardiovascular Risk Factors Management: Emerging Challenges and Strategies for Prevention and Adaptation.

European journal of preventive cardiology·2026
Same author

A natural experiment in the air: particulate matter and acute myocardial infarction subtypes during the COVID-19 pandemic.

European heart journal·2026
Same journal

Rethinking triglycerides in the management of ASCVD.

European journal of preventive cardiology·2026
Same journal

Mapping the continuum: polygenic risk of coronary artery disease.

European journal of preventive cardiology·2026
Same journal

Why is Transition so Relevant to Prevention in Congenital Heart Disease? Start Early, Educate, Empower Families and Patients.

European journal of preventive cardiology·2026
Same journal

Beyond Awareness and Diagnosis: From Knowledge to Action for Blood Pressure Control in Coronary Artery Disease.

European journal of preventive cardiology·2026
Same journal

Harmonica-based breathing exercises during hybrid cardiac telerehabilitation: a randomized controlled trial (HARMONY CR).

European journal of preventive cardiology·2026
Same journal

First count the particles: ApoB, the LDL-C/TC ratio, and the hierarchy of lipid risk assessment.

European journal of preventive cardiology·2026
See all related articles

Related Experiment Video

Updated: Oct 11, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.7K

Editor comment: Focus on heart failure

Geza Halasz1, Massimo F Piepoli2

  • 1Cardiac Unit, G. da Saliceto Hospital, AUSL Piacenza and University of Parma, Italy.

European Journal of Preventive Cardiology
|December 5, 2021
PubMed
Summary

No abstract available in PubMed .

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

922

Related Experiment Videos

Last Updated: Oct 11, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.7K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

922